Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+8.3%
3 months
-15.5%
6 months
+7.3%
1 year
-0.8%
Year to date
-9.1%
52-week range
$28.63 – $47.44
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$18.29B
P/E
-5.3
P/B
1.4
P/S
0.8
Revenue
$24.18B
Net income
-$3.46B
Diluted EPS
-6.72
Gross margin
29.80%
Net margin
-14.30%
Return on equity
-24.20%
Total debt
$12.27B
Cash
$815M
Free cash flow
$288M
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$6.2B
-$1.13B
31.20%
-18.20%
-$195M
Jun 30, 2026
$6B
-$12M
27.60%
-0.20%
$3M
Mar 31, 2026
$5.97B
$60M
28.90%
1.00%
$115M
Dec 31, 2025
$6.01B
-$2.38B
31.40%
-39.70%
$365M
Sep 30, 2025
$6.22B
-$1.1B
31.10%
-17.70%
$165M
Jun 30, 2025
$6.77B
$75M
27.90%
1.10%
$64M
Mar 31, 2025
$5.9B
-$105M
27.80%
-1.80%
-$535M
Dec 31, 2024
$4.58B
-$147M
29.00%
-3.20%
$223M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
This article examines how an $800,000 portfolio split equally among Altria, Edison International, International Paper, and AT&T could generate over $44,000 in annual passive income. It details the yield and risks associated with each company, highlighting International Paper's weak dividend coverage and Edison International's wildfire liabilities, while noting Altria's high yield and AT&T's commitment to its dividend through 2028. The author emphasizes that steady cash flow from staggered quarterly payments is crucial for retirees.
ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease business by adding EMCITATE, an approved treatment for MCT8 deficiency, which ANI estimates could achieve peak sales of over $300 million with patent protection extending into mid-2045. Egetis's board unanimously recommends the offer, and shareholders representing about 42% of outstanding shares have committed to accept, with the deal contingent on 90% shareholder acceptance and regulatory approvals.
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.
JACKSON, Miss. (WJTV) - The Mississippi Department of Human Services (MDHS), Division of Aging and Adult Services (DAAS), announced the State Health Insurance Program (SHIP) will provide assistance for...
International Paper reported a $1.10 billion Q3 loss from continuing operations, primarily due to a $1.38 billion non-cash goodwill impairment charge for its EMEA packaging business. Despite the loss, the company aims for $460 million to $500 million in North American operating profit for Q4 and $1.3 billion to $1.4 billion for full-year 2026, while also advancing the separation of its EMEA packaging business. Softer demand and rising costs for paper, fiber, energy, and fuel contributed to reduced sales volumes, although North American packaging saw improved operating profit compared to the previous year.
Sports betting companies prey on customers who lose the most money, but they place strict limits on those who consistently beat the house, CBS News reported Monday. Sports gambling companies reward their biggest losers, gifting them VIP access to sporting events and signed memorabilia, according to CBS News.